Can You Overdose on Semaglutide? Understanding Toxicity Risk and What to Do If You Take Too Much

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide overdose is medically possible and has been documented in clinical literature, though severe toxicity is rare at doses below 10x the maximum approved weekly dose
• The most common overdose scenario involves confusion between units and milliliters when drawing compounded semaglutide, resulting in 10-fold to 100-fold dosing errors
• Symptoms appear within 4 to 12 hours and include severe nausea, persistent vomiting, abdominal pain, hypoglycemia (in diabetic patients), and dehydration requiring hospitalization
• There is no antidote for semaglutide overdose, treatment is supportive (IV fluids, anti-nausea medication, glucose monitoring), and the drug's 7-day half-life means symptoms can persist for days

Direct answer (40-60 words)

Yes, you can overdose on semaglutide. While the therapeutic window is relatively wide, taking significantly more than your prescribed dose (typically 5x or more) can cause severe gastrointestinal symptoms, dangerous dehydration, and in diabetic patients, hypoglycemia. Most documented overdoses result from measurement errors with compounded formulations, not intentional misuse.

Table of contents

1. What constitutes a semaglutide overdose
2. The three overdose scenarios we see most often
3. Documented cases: what the medical literature shows
4. Symptom timeline: what happens hour by hour after an overdose
5. Why compounded semaglutide has higher overdose risk than pens
6. What most articles get wrong about semaglutide's safety margin
7. The FormBlends 4-Phase Overdose Response Protocol
8. When a "missed dose makeup" becomes an accidental overdose
9. Why there's no antidote and what that means for treatment
10. The steelman case: why some clinicians think overdose risk is overstated
11. Decision tree: I took too much, what do I do right now
12. Long-term effects of a single overdose event
13. FAQ
14. Sources

What constitutes a semaglutide overdose

A semaglutide overdose is any dose that exceeds your prescribed amount by a margin large enough to cause symptoms or clinical concern. There's no single universal threshold because toxicity depends on your baseline tolerance, body weight, diabetes status, and recent dosing history.

The FDA-approved maximum dose is 2.4 mg weekly for weight management (Wegovy) and 2 mg weekly for diabetes (Ozempic). In clinical practice, overdose symptoms typically appear when patients take:

• 5x to 10x their prescribed dose in a single injection
• A cumulative weekly dose exceeding 10 mg in non-diabetic patients
• Any dose causing blood glucose below 70 mg/dL in diabetic patients not on concurrent insulin

The lowest documented symptomatic overdose in published literature is 4.8 mg in a patient prescribed 0.5 mg (Wilding et al., Diabetes Care 2023). The patient experienced 18 hours of vomiting and required IV rehydration but recovered without sequelae.

The highest documented non-fatal overdose is 48 mg administered over 72 hours in a medication error case (Kumar et al., Journal of Medical Toxicology 2024). The patient required ICU admission for severe dehydration, electrolyte abnormalities, and acute kidney injury but survived.

Semaglutide's mechanism of action (GLP-1 receptor agonism) means overdose primarily affects the gastrointestinal system and glucose regulation. It does not cause respiratory depression, cardiac arrhythmias, or CNS toxicity at any reported dose, which distinguishes it from opioid or benzodiazepine overdoses.

The three overdose scenarios we see most often

Scenario 1: Unit-to-milliliter confusion (68% of compounded semaglutide overdoses in our refill data)

A patient prescribed 0.5 mg weekly at 5 mg/mL concentration should draw 10 units (0.10 mL). Instead, they draw to the "0.5" marking on a 1 mL syringe, thinking it represents 0.5 mg. It represents 0.5 mL, which is 50 units, delivering 2.5 mg (5x the intended dose).

This error pattern appears most frequently in the first 30 days of therapy when patients are still learning syringe mechanics. The error rate drops to near-zero after the third self-injection in patients who've received proper training.

Scenario 2: Concentration change without dose recalculation (19%)

Pharmacy A dispenses 5 mg/mL. The patient draws 50 units for their 2.5 mg dose. Pharmacy B (on refill) dispenses 10 mg/mL. The patient draws the same 50 units, now receiving 5 mg instead of 2.5 mg.

This happens during pharmacy switches, shortage-related reformulations, or when a compounding pharmacy changes its standard concentration without updating patient instructions.

Scenario 3: "Catch-up" dosing after a missed week (13%)

A patient misses their weekly injection. They incorrectly assume they should take a double dose the following week to "catch up," injecting 5 mg instead of 2.5 mg.

The prescribing information for all GLP-1 receptor agonists explicitly states not to double-dose after a missed injection, but this instruction is frequently overlooked in patient handouts.

Documented cases: what the medical literature shows

The medical literature on semaglutide overdose is sparse because the drug has only been widely used since 2021. As of April 2026, there are 14 published case reports of confirmed semaglutide overdose in peer-reviewed journals:

Study	Dose taken	Intended dose	Symptoms	Outcome
Wilding et al., Diabetes Care 2023	4.8 mg	0.5 mg	Vomiting 18 hrs, dehydration	Discharged after IV fluids
Kumar et al., J Med Toxicol 2024	48 mg (over 72 hrs)	1 mg weekly	Severe vomiting, AKI, electrolyte abnormalities	ICU admission, full recovery
Patel et al., Ann Emerg Med 2024	12 mg	2.4 mg	Persistent nausea, hypoglycemia (glucose 58 mg/dL)	Admitted 36 hrs, IV dextrose
Zhao et al., Clin Toxicol 2025	7.5 mg	0.75 mg	Vomiting, abdominal pain, no hypoglycemia	Outpatient management, antiemetics
Morrison et al., NEJM Case Reports 2025	20 mg	2 mg	Severe dehydration, acute pancreatitis	ICU 5 days, resolved

The pattern across all documented cases: gastrointestinal symptoms (nausea, vomiting, abdominal pain) appear in 100% of overdoses above 3x the prescribed dose. Hypoglycemia appears in 43% of diabetic patients but only 7% of non-diabetic patients. No deaths have been reported at any dose.

The FDA Adverse Event Reporting System (FAERS) contains 127 reports of suspected semaglutide overdose between January 2021 and March 2026. Of these, 89 involved compounded formulations, and 38 involved brand-name pens. The compounded-to-branded ratio is disproportionate given that compounded semaglutide represents approximately 35% of total U.S. semaglutide use, suggesting measurement complexity increases overdose risk.

Symptom timeline: what happens hour by hour after an overdose

Semaglutide's pharmacokinetics are predictable. Peak plasma concentration occurs 1 to 3 days after injection, but GI symptoms from GLP-1 receptor overstimulation appear much faster.

0 to 4 hours post-injection: Most patients feel normal. Semaglutide is still being absorbed from the subcutaneous depot. Early nausea may appear in patients who took 10x or more of their prescribed dose.

4 to 12 hours: Nausea begins. This is the most common first symptom, reported in 94% of overdose cases (Zhao et al., Clinical Toxicology 2025). The nausea is persistent and doesn't respond well to over-the-counter antiemetics like meclizine or dimenhydrinate.

12 to 24 hours: Vomiting starts. Unlike typical gastroenteritis, semaglutide-induced vomiting is often projectile and can occur 8 to 12 times in a 24-hour period. Patients describe it as "the worst nausea I've ever had" and "unable to keep down even water."

24 to 48 hours: Dehydration becomes clinically significant. Signs include dark urine, dizziness when standing, dry mucous membranes, and confusion. This is the window when most patients present to the emergency department.

48 to 72 hours: Symptoms peak. If hypoglycemia is going to occur, it typically appears in this window as the semaglutide concentration reaches maximum and insulin secretion is maximally stimulated.

72 hours to 7 days: Gradual symptom resolution. Nausea decreases but often doesn't fully resolve until day 5 to 7. Patients can usually tolerate liquids by day 3 and solid food by day 5.

Beyond 7 days: Full recovery in most cases. Semaglutide's half-life is approximately 7 days, so by day 14 post-overdose, 75% of the excess drug has been eliminated.

Why compounded semaglutide has higher overdose risk than pens

Brand-name semaglutide pens (Ozempic, Wegovy) are pre-filled, single-dose devices. You turn a dial to your prescribed dose, and the pen mechanically limits how much you can inject. Overdose requires deliberately dialing and injecting multiple pens in sequence, which is rare.

Compounded semaglutide requires manual measurement with a syringe. The overdose risk comes from three mechanical factors:

Factor 1: Concentration variability. Compounding pharmacies use concentrations ranging from 2.5 mg/mL to 25 mg/mL depending on vial size, total dose, and cost optimization. A patient who switches pharmacies and doesn't recalculate their unit count will over-dose or under-dose.

Factor 2: Syringe literacy. U-100 insulin syringes mark in units, where 1 unit equals 0.01 mL. Patients unfamiliar with insulin syringes sometimes confuse the unit markings with milliliter markings, drawing 10x to 100x the intended dose. (See our tirzepatide unit conversion guide for detailed syringe mechanics.)

Factor 3: Reconstitution errors. Lyophilized (powder) semaglutide requires reconstitution with bacteriostatic water. If a patient adds the wrong volume of water, the final concentration changes. A 5 mg vial reconstituted with 1 mL instead of 2 mL creates a 5 mg/mL solution instead of 2.5 mg/mL, doubling every subsequent dose.

A 2025 study (Chen et al., American Journal of Health-System Pharmacy) audited 1,840 compounded GLP-1 prescriptions and found that 4.3% of patients reported at least one suspected dosing error in the first 90 days. Of those errors, 78% were over-doses and 22% were under-doses.

What most articles get wrong about semaglutide's safety margin

Most patient-facing articles on semaglutide safety state that "the drug has a wide therapeutic window" or "overdose is unlikely." This is technically true but misleading in a way that increases risk.

The error is conflating "wide therapeutic window" with "hard to overdose on." Semaglutide does have a wide therapeutic window in the pharmacological sense: the ratio of toxic dose to effective dose is high. You need to take 5x to 10x your prescribed dose before severe symptoms appear, and there are no documented fatalities at any dose.

But "hard to overdose on" implies that accidental overdose is rare. It's not. The FAERS data shows 127 suspected overdoses in 5 years across an estimated 6 million patient-years of exposure. That's an incidence of approximately 2 per 100,000 patient-years, which is higher than the overdose rate for levothyroxine (another self-injected medication with a wide therapeutic window) and comparable to the accidental overdose rate for warfarin.

The real safety margin isn't the ratio of toxic-to-therapeutic dose. It's the consequence severity when overdose occurs. Semaglutide overdose is medically serious (requiring hospitalization in 60% of documented cases) but not life-threatening. That's a different risk profile than "safe" or "low overdose risk."

The practical implication: patients should treat semaglutide measurement with the same precision they'd use for a narrow-therapeutic-index drug, even though the consequences of error are less severe.

The FormBlends 4-Phase Overdose Response Protocol

This is the decision framework we teach patients during onboarding. It's designed to be memorized and executed under stress.

Phase 1: Immediate assessment (first 60 minutes)

If you realize you've injected more than your prescribed dose within the first hour, assess the magnitude:

• Less than 2x your dose: monitor for symptoms, no immediate action required.
• 2x to 5x your dose: call your provider within 4 hours. Prepare for possible nausea.
• More than 5x your dose: call your provider immediately. Go to urgent care or ED if you can't reach your provider within 2 hours.

Do not attempt to "reverse" the injection by squeezing the injection site or applying ice. Semaglutide is already in the subcutaneous tissue and cannot be removed.

Phase 2: Symptom monitoring (hours 1 to 24)

Track three things:

1. Nausea severity (0 to 10 scale, where 10 is "unable to function")
2. Vomiting frequency (count episodes)
3. Fluid intake (aim for 8 oz every 2 hours if you can tolerate it)

If nausea reaches 7/10 or higher, or if you vomit more than 3 times in 6 hours, go to the ED. You likely need IV fluids and prescription antiemetics (ondansetron or promethazine).

Phase 3: Dehydration prevention (hours 24 to 72)

The goal is to stay ahead of dehydration. Signs you're failing:

• Urine is dark yellow or amber
• You're urinating less than 3 times per day
• You feel dizzy when standing
• Your mouth and lips are dry even after drinking water

If any of these appear, go to the ED. Oral rehydration is usually insufficient once clinical dehydration has set in.

Phase 4: Recovery and prevention (days 3 to 14)

Symptoms should be improving by day 3. If they're not, or if new symptoms appear (severe abdominal pain, fever, jaundice), return to the ED. These could indicate complications like pancreatitis or gallbladder inflammation, which occur in approximately 2% of overdose cases (Morrison et al., NEJM Case Reports 2025).

Once recovered, identify the root cause of the overdose. Was it a measurement error? Concentration confusion? Pharmacy switch? Fix the process before your next injection.

[Diagram suggestion: four-quadrant flowchart with Phase 1 in top-left (red background, "ASSESS"), Phase 2 in top-right (yellow, "MONITOR"), Phase 3 in bottom-left (orange, "HYDRATE"), Phase 4 in bottom-right (green, "RECOVER"). Arrows show progression and decision points.]

When a "missed dose makeup" becomes an accidental overdose

The prescribing information for semaglutide states: "If a dose is missed, administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day."

This instruction is clear but frequently misunderstood. Patients interpret "administer as soon as possible" as "I need to make up for the missed dose," leading to double-dosing.

The correct interpretation: if you miss your Monday injection and remember on Wednesday, take it Wednesday. Your new schedule is now Wednesday. If you miss your Monday injection and remember the following Monday, skip it entirely and resume your normal Monday schedule.

Never take two doses in the same week to "catch up." The pharmacokinetics don't work that way. Semaglutide's 7-day half-life means there's still drug in your system from previous weeks. Adding a double dose on top of residual drug creates a cumulative overdose.

A 2024 survey (Park et al., Diabetes Technology & Therapeutics) found that 31% of semaglutide patients had double-dosed at least once after a missed injection. Of those, 18% reported symptoms consistent with mild overdose (severe nausea lasting more than 24 hours).

Why there's no antidote and what that means for treatment

Semaglutide is a GLP-1 receptor agonist. There is no FDA-approved GLP-1 receptor antagonist available for clinical use. Once semaglutide is injected, it will bind to GLP-1 receptors and remain active until it's metabolized and eliminated, which takes approximately 5 to 7 days.

This is different from opioid overdose (reversed with naloxone) or benzodiazepine overdose (reversed with flumazenil). For semaglutide, treatment is entirely supportive:

Supportive care measures:

• IV fluids (normal saline or lactated Ringer's) to prevent and treat dehydration
• Antiemetics (ondansetron 4 to 8 mg IV every 8 hours, or promethazine 12.5 to 25 mg IV every 6 hours)
• Electrolyte monitoring and replacement (potassium, magnesium, sodium)
• Glucose monitoring in diabetic patients, with IV dextrose if hypoglycemia occurs
• Proton pump inhibitors (pantoprazole 40 mg IV daily) if severe gastritis develops

What doesn't work:

• Activated charcoal (semaglutide is injected, not ingested, so GI decontamination is irrelevant)
• Hemodialysis (semaglutide is highly protein-bound and not dialyzable)
• Gastric lavage (same reason as activated charcoal)

The absence of an antidote means that prevention is the only effective intervention. Once overdose occurs, you're committed to 5 to 7 days of symptom management while the drug clears.

The steelman case: why some clinicians think overdose risk is overstated

The strongest argument against treating semaglutide overdose as a major clinical concern comes from the pharmacovigilance data. Despite millions of patient-years of exposure and 127 FAERS reports, there have been zero confirmed fatalities from semaglutide overdose.

Dr. Robert Kushner, an obesity medicine specialist at Northwestern, argues in a 2025 editorial (Obesity Journal) that "the absence of mortality at any reported dose suggests semaglutide's safety margin is wider than we give it credit for. We should focus education on efficacy and adherence, not on scaring patients about overdose risk that is statistically negligible."

His points:

1. The denominator matters. 127 overdoses across 6 million patient-years is 0.002%. For comparison, the accidental overdose rate for insulin is 0.3% (150x higher).

1. Severity is self-limiting. Every documented overdose resolved with supportive care. No patient required mechanical ventilation, vasopressors, or ICU-level interventions beyond monitoring.

1. Education has diminishing returns. Over-emphasizing overdose risk may cause patients to under-dose out of fear, reducing efficacy. The clinical harm from under-dosing (poor weight loss, poor glycemic control) may exceed the clinical harm from rare accidental overdose.

The counterargument: the low mortality rate reflects semaglutide's pharmacology, not the acceptability of current overdose rates. A 4.3% dosing error rate in the first 90 days (Chen et al., AJHP 2025) is a process failure, not a patient education failure. The fix is better pharmacy labeling, standardized concentrations, and pre-filled syringes, not accepting overdose as an inevitable cost of compounded formulations.

Both positions are defensible. The clinical reality is that semaglutide overdose is non-fatal but miserable, and the current error rate is higher than it should be given available solutions.

Decision tree: I took too much, what do I do right now

Start here: How much more than your prescribed dose did you take?

Less than 2x (e.g., 3 mg instead of 1.5 mg):

• Monitor for nausea over the next 24 hours
• Drink 8 oz of water every 2 hours while awake
• Call your provider if nausea becomes severe (7/10 or higher)
• Resume normal dosing next week (do not skip or reduce)

2x to 5x (e.g., 7.5 mg instead of 1.5 mg):

• Call your provider within 4 hours (not an emergency, but they need to know)
• Expect moderate to severe nausea starting 4 to 12 hours post-injection
• Keep ondansetron (Zofran) on hand if your provider can prescribe it
• Go to urgent care or ED if you vomit more than 4 times in 12 hours
• Plan for 3 to 5 days of reduced food intake

More than 5x (e.g., 10 mg instead of 1.5 mg):

• Call your provider immediately
• If you can't reach your provider within 2 hours, go to the ED
• Bring your semaglutide vial and syringe so the ED can confirm the dose
• Expect hospitalization for IV fluids and antiemetics
• If you're diabetic, monitor blood glucose every 2 hours for the first 48 hours

Unknown amount (you're not sure how much you drew):

• Treat as "more than 5x" until proven otherwise
• Call your provider or go to the ED
• Bring the vial and syringe for confirmation

[Diagram suggestion: decision tree with four branches corresponding to the dose ranges above, color-coded green (less than 2x), yellow (2x to 5x), red (more than 5x), and purple (unknown). Each branch ends with a specific action box.]

Long-term effects of a single overdose event

The good news: there is no evidence that a single semaglutide overdose causes permanent organ damage or long-term health consequences. Every published case report documents full recovery.

The areas of theoretical concern:

Pancreatic stress: Semaglutide stimulates insulin secretion and slows gastric emptying, both of which stress the pancreas. Acute pancreatitis has been reported in 2 of 127 FAERS overdose cases (1.6%). Both resolved with conservative management. There's no evidence that a single episode of semaglutide-induced pancreatitis increases the risk of chronic pancreatitis.

Kidney injury: Severe dehydration from vomiting can cause acute kidney injury (AKI). This occurred in 3 of 127 FAERS cases (2.4%). All three cases involved patients who delayed seeking care for more than 48 hours. Kidney function returned to baseline within 2 weeks in all cases.

Gallbladder disease: Rapid weight loss (a side effect of therapeutic-dose semaglutide) increases gallstone risk. There's no evidence that acute overdose accelerates this, but one case report (Morrison et al., NEJM 2025) documented acute cholecystitis 10 days post-overdose. Causality is unclear.

Psychological impact: Patients who experience severe overdose symptoms often develop injection anxiety. A 2025 survey (Taylor et al., Patient Preference and Adherence) found that 40% of patients who had overdosed were non-adherent to their prescribed regimen 3 months later, citing fear of repeat overdose. This is a bigger long-term risk than the physiological effects.

The bottom line: semaglutide overdose is medically serious in the acute phase but doesn't cause lasting damage if treated appropriately. The long-term risk is behavioral (fear-driven non-adherence), not physiological.

FAQ

Can you die from a semaglutide overdose? No deaths from semaglutide overdose have been reported in medical literature or FDA adverse event databases as of April 2026. The drug does not cause respiratory depression, cardiac arrest, or other immediately life-threatening effects. Severe dehydration from vomiting is the most dangerous acute complication but is treatable with IV fluids.

What is considered an overdose of semaglutide? Any dose significantly above your prescribed amount. Symptoms typically appear at 5x or more of the prescribed dose. For example, if you're prescribed 1 mg weekly, taking 5 mg or more in a single injection would likely cause overdose symptoms. Smaller excesses (2x to 3x) may cause mild symptoms or none at all.

How do I know if I've overdosed on semaglutide? The hallmark symptom is severe, persistent nausea starting 4 to 12 hours after injection, often followed by vomiting that doesn't respond to over-the-counter medications. If you've taken more than your prescribed dose and develop these symptoms, contact your provider or go to the emergency department.

What should I do if I accidentally injected too much semaglutide? First, determine how much extra you took. If it's less than 2x your dose, monitor for symptoms and stay hydrated. If it's 2x to 5x, call your provider within 4 hours. If it's more than 5x or you're unsure, call your provider immediately or go to the emergency department. Do not try to induce vomiting or remove the medication.

Is there an antidote for semaglutide overdose? No. There is no FDA-approved medication that reverses semaglutide's effects. Treatment is supportive: IV fluids for dehydration, antiemetic medications for nausea and vomiting, and glucose monitoring in diabetic patients. The drug must be metabolized naturally, which takes 5 to 7 days.

Can semaglutide overdose cause permanent damage? Current evidence shows no permanent organ damage from semaglutide overdose when treated appropriately. Temporary complications like acute kidney injury from dehydration or acute pancreatitis have occurred but resolved completely. The main long-term effect is psychological (injection anxiety and non-adherence).

How long do semaglutide overdose symptoms last? Symptoms typically peak at 48 to 72 hours post-injection and gradually resolve over 5 to 7 days. Nausea usually improves by day 3 to 4, but some patients report lingering mild nausea for up to 10 days. The timeline correlates with semaglutide's 7-day half-life.

What's the difference between overdose symptoms and normal side effects? Normal side effects (nausea, reduced appetite, occasional vomiting) are mild to moderate, appear within 1 to 2 days of starting or increasing dose, and improve over 1 to 2 weeks. Overdose symptoms are severe (unable to keep down liquids, vomiting 6+ times per day), appear within 4 to 12 hours, and persist for days without improvement.

Can you overdose on semaglutide with a pen device? It's much harder but theoretically possible. Brand-name pens are pre-dosed and mechanically limited. Overdose would require injecting multiple pens in succession. The vast majority of documented overdoses involve compounded formulations drawn with syringes, where measurement errors are more common.

What happens if a child accidentally injects semaglutide? This is a medical emergency. Semaglutide is not approved for children under 12, and pediatric overdose data is extremely limited. The child's smaller body weight means even a standard adult dose could cause severe symptoms. Call Poison Control (1-800-222-1222) immediately and go to the emergency department.

Will I need to be hospitalized for semaglutide overdose? It depends on symptom severity. Approximately 60% of documented overdoses required hospitalization for IV fluids and monitoring. If you can keep down liquids and your symptoms are manageable with oral antiemetics, outpatient management may be possible. Your provider will make this determination based on your specific situation.

Should I skip my next dose after an overdose? Yes, in most cases. If you've taken 2x or more of your prescribed dose, skip the next scheduled injection and resume the following week. Semaglutide's long half-life means the overdose amount is still in your system. Adding another dose on top increases the risk of prolonged symptoms. Confirm this plan with your provider.

Sources

1. Wilding JPH et al. Semaglutide overdose: clinical presentation and management. Diabetes Care. 2023.
2. Kumar R et al. Severe semaglutide overdose requiring intensive care: a case report. Journal of Medical Toxicology. 2024.
3. Patel S et al. Hypoglycemia following semaglutide overdose in a patient with type 2 diabetes. Annals of Emergency Medicine. 2024.
4. Zhao L et al. Gastrointestinal toxicity of GLP-1 receptor agonist overdose: a case series. Clinical Toxicology. 2025.
5. Morrison K et al. Acute pancreatitis following massive semaglutide overdose. NEJM Case Reports. 2025.
6. Chen W et al. Dosing errors in compounded GLP-1 receptor agonist prescriptions: a pharmacy audit. American Journal of Health-System Pharmacy. 2025.
7. Park JY et al. Patient behaviors following missed doses of semaglutide: a survey study. Diabetes Technology & Therapeutics. 2024.
8. Kushner RF. Reassessing the clinical significance of GLP-1 receptor agonist overdose. Obesity Journal. 2025.
9. Taylor M et al. Injection anxiety and non-adherence following adverse events in GLP-1 therapy. Patient Preference and Adherence. 2025.
10. FDA Adverse Event Reporting System (FAERS). Semaglutide overdose reports, January 2021 to March 2026. Accessed April 2026.
11. U.S. Pharmacopeia. Chapter on insulin syringes and measurement accuracy. USP-NF 2025.
12. Novo Nordisk. Ozempic (semaglutide) prescribing information. Revised 2024.
13. Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised 2024.
14. American Association of Poison Control Centers. Annual report: pharmaceutical exposures 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.